MyCural develops novel small molecule inhibitors targeting the MYC oncoprotein, a key driver in over 50% of human cancers. The company utilizes innovative methods to overcome challenges associated with designing drugs against the disordered structure of MYC. Their focus is advancing candidate therapeutics to treat patients with MYC-driven cancers and aggressive tumors.
Funding
Funding not disclosed
Founders
Product
Problem
Many cancers are driven by the MYC oncoprotein, but its disordered structure makes it difficult to target with traditional drug design methods, leaving a significant unmet need for effective therapies against MYC-driven tumors. These high-risk tumors are often deemed "undruggable" by conventional approaches.
Solution
MyCural Therapeutics is developing small molecule inhibitors that selectively bind to and inhibit the MYC oncoprotein in tumor cells. This targeted approach aims to selectively kill MYC-driven tumor cells while sparing normal cells, offering a potential new therapy for patients with aggressive, high-risk cancers. By focusing on innovative methods to identify inhibitors, MyCural Therapeutics seeks to overcome the challenges associated with targeting the disordered structure of MYC. The company's candidate drugs are designed to address cancers where MYC is a primary driver.
Target Audience
The primary target audience includes patients with MYC-driven cancers and aggressive, high-risk tumors, as well as oncologists and researchers seeking new therapeutic options for these challenging cancers.
Features
- Small molecule inhibitors designed to bind to the MYC oncoprotein
- Selective inhibition of MYC in tumor cell lines
- Designed to spare normal cells, reducing potential side effects
- Focus on MYC-driven cancers and aggressive high-risk tumors